San Diego–based Resmed calls Smart Comfort (which was submitted to the FDA as “Personalized Therapy Comfort Settings, or PTCS) the first FDA-cleared, AI-enabled medical device that recommends personalized comfort settings, helping people with obstructive sleep apnea (OSA) start and stay on continuous positive airway pressure (CPAP) therapy.

The company plans to begin rolling out a limited U.S. beta version of Smart Comfort early next year. It initially targets new users of the myAir consumer sleep companion app, paired with the AirSense 11 device. Then, Resmed plans for a broader U.S. rollout to new myAir users later in 2026.